Chondromalacia patellae

Summary

Chondromalacia patellae (MONDO:0008207) is a disease and 10 clinical trials. Top therapeutic interventions include dextrose. A subtype of chondromalacia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	chondromalacia patellae
Mondo ID	MONDO:0008207
MeSH	D046789
OMIM	168900
Orphanet	1428
DOID	DOID:13357
ICD-10-CM	M22.4
ICD-11	1589625540
SNOMED CT	36071006
UMLS	C0008475
MedGen	939
GARD	0024609
Anatomy (UBERON)	UBERON:0002446
Is cancer (heuristic)	no

Also known as: chondromalacia of patella · chondromalacia patellae · patella chondromalacia

Disease family

This is a subtype of chondromalacia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › arthropathy › articular cartilage disorder › chondromalacia › chondromalacia patellae

Related subtypes (1): relapsing polychondritis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	10

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01434966	Not specified	COMPLETED	Changes in Quadriceps Function Following Local or Distant Interventions in Individuals With Patellofemoral Pain
NCT02012413	Not specified	COMPLETED	Effect of Pulsed Signal Therapy in Patella Chondromalacia
NCT03515720	Not specified	COMPLETED	Neuroprolotherapy With Physical Therapy for Treatment of Patellar Chondromalacia
NCT04589702	Not specified	COMPLETED	Temporal Activation of Core Muscles and Vasti in Isolated Patellofemoral Osteoarthritis
NCT04669834	Not specified	COMPLETED	Effect of Core Stability Exercise on Isolated Patellofemoral Osteoarthritis.
NCT04796103	Not specified	COMPLETED	The Effectiveness of Prolotherapy (%5 Dextros) in the Treatment of Patients With Chondromalacia Patella
NCT05096520	Not specified	UNKNOWN	Intermedius Genicular Nerve in the Treatment of Patients With Chondromalacia Patella
NCT05407077	Not specified	COMPLETED	Is Lower Limb Neuromotor Control Diverse in Females With PF OA Contrasted With Asymptomatic Controls
NCT05597670	Not specified	COMPLETED	Effect of Proximal Stabilization on Recruitment of the Core & Vasti in Patellofemoral Arthritis During Descending Stairs
NCT06020794	Not specified	COMPLETED	The Efficacy of LPPRP in the Treatment of Chondromalacia Patella

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEXTROSE	4	1